These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 31238631)

  • 21. Long-term Outcome of an Organ Preservation Program After Neoadjuvant Treatment for Rectal Cancer.
    Martens MH; Maas M; Heijnen LA; Lambregts DM; Leijtens JW; Stassen LP; Breukink SO; Hoff C; Belgers EJ; Melenhorst J; Jansen R; Buijsen J; Hoofwijk TG; Beets-Tan RG; Beets GL
    J Natl Cancer Inst; 2016 Dec; 108(12):. PubMed ID: 27509881
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Long-term outcome of patients with rectal cancer who achieve complete or near complete clinical responses after neoadjuvant therapy: a multicenter registry study of data from the Chinese Watch and Wait Database].
    Zhao YM; Wang WH; Zhang W; Wang L; Li S; Wang JW; Liao LE; Yu GY; Sun Z; Qu YL; Gong Y; Lu Y; Wu T; Li YF; Wang Q; Zhao GH; Xiao Y; Ding PR; Zhang Z; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Apr; 27(4):372-382. PubMed ID: 38644243
    [No Abstract]   [Full Text] [Related]  

  • 23. [Guiding significance of pathological diagnosis in watch and wait strategy for locally advanced rectal cancer patients after neoadjuvant therapy].
    Li ZW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):248-251. PubMed ID: 32192303
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Application of imaging diagnosis in watch and wait strategy for locally advanced rectal cancer patients after neoadjuvant therapy].
    Zhang XY; Lu QY; Sun YS
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):243-247. PubMed ID: 32192302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.
    Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J;
    BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low rectal cancer treatment strategies: a cohort study assessing watch and wait.
    Pinto JC; Pereira AD; Pimenta A; Pedro C; Fernandez G; Marques I; Miguel I; Freire J; Maciel J; Venâncio J; D'Orey L; Mirones L; Limbert M; Labareda M; Chaves P; Fonseca R; Barroca R; Ferreira T; Marques T; Rosa I
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2631-2638. PubMed ID: 32435893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oncologic outcomes of watch-and-wait strategy or surgery for low to intermediate rectal cancer in clinical complete remission after adjuvant chemotherapy: a systematic review and meta-analysis.
    Tan S; Gao Q; Cui Y; Ou Y; Huang S; Feng W
    Int J Colorectal Dis; 2023 Oct; 38(1):246. PubMed ID: 37787779
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Watch and wait: Why, to whom and how.
    Cerdán-Santacruz C; Vailati BB; São Julião GP; Habr-Gama A; Perez RO
    Surg Oncol; 2022 Aug; 43():101774. PubMed ID: 35491334
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is neoadjuvant chemoradiation with dose-escalation and consolidation chemotherapy sufficient to increase surgery-free and distant metastases-free survival in baseline cT3 rectal cancer?
    São Julião GP; Habr-Gama A; Vailati BB; Aguilar PB; Sabbaga J; Araújo SEA; Mattacheo A; Alexandre FA; Fernandez LM; Gomes DB; Gama-Rodrigues J; Perez RO
    Eur J Surg Oncol; 2018 Jan; 44(1):93-99. PubMed ID: 29217398
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Dynamic Clinical Calculator for Estimating Conditional Recurrence-Free Survival After Total Neoadjuvant Therapy for Rectal Cancer and Either Surgery or Watch-and-Wait Management.
    Weiser MR; Chou JF; Kim JK; Widmar M; Wei IH; Pappou EP; Smith JJ; Nash GM; Paty PB; Cercek A; Saltz LB; Romesser PB; Crane CH; Garcia-Aguilar J; Schrag D; Gönen M
    JAMA Netw Open; 2022 Sep; 5(9):e2233859. PubMed ID: 36173634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes after the watch-and-wait strategy and local excision treatment for rectal cancer: a meta-analysis.
    Li J; Ma Y; Wen L; Zhang G; Yao X
    Expert Rev Anticancer Ther; 2023 May; 23(5):555-564. PubMed ID: 36795784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Organ Preservation in cT2N0 Rectal Cancer After Neoadjuvant Chemoradiation Therapy: The Impact of Radiation Therapy Dose-escalation and Consolidation Chemotherapy.
    Habr-Gama A; São Julião GP; Vailati BB; Sabbaga J; Aguilar PB; Fernandez LM; Araújo SEA; Perez RO
    Ann Surg; 2019 Jan; 269(1):102-107. PubMed ID: 28742703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study.
    van der Valk MJM; Hilling DE; Bastiaannet E; Meershoek-Klein Kranenbarg E; Beets GL; Figueiredo NL; Habr-Gama A; Perez RO; Renehan AG; van de Velde CJH;
    Lancet; 2018 Jun; 391(10139):2537-2545. PubMed ID: 29976470
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short-course radiotherapy combined with CAPOX and Toripalimab for the total neoadjuvant therapy of locally advanced rectal cancer: a randomized, prospective, multicentre, double-arm, phase II trial (TORCH).
    Wang Y; Shen L; Wan J; Zhang H; Wu R; Wang J; Wang Y; Xu Y; Cai S; Zhang Z; Xia F
    BMC Cancer; 2022 Mar; 22(1):274. PubMed ID: 35291966
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Watch and Wait Strategy for Rectal Cancer: How Long Should We Wait for a Clinical Complete Response?
    Asoglu O; Goksoy B; Aliyev V; Mustafayev TZ; Atalar B; Bakir B; Guven K; Demir G; Goksel S
    Surg Technol Int; 2022 May; 40():130-139. PubMed ID: 35090178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Total Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-analysis.
    Kasi A; Abbasi S; Handa S; Al-Rajabi R; Saeed A; Baranda J; Sun W
    JAMA Netw Open; 2020 Dec; 3(12):e2030097. PubMed ID: 33326026
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 'Watch and wait' in rectal cancer: summary of the current evidence.
    On J; Aly EH
    Int J Colorectal Dis; 2018 Sep; 33(9):1159-1168. PubMed ID: 29978363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Reassessment of practice of Chinese surgeons since introduction of the watch and wait strategy after neoadjuvant therapy for rectal cancer].
    Zhao MH; Sun TT; Wang L; Huang YL; Xie XY; Lu Y; Zhao GH; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Apr; 27(4):383-394. PubMed ID: 38644244
    [No Abstract]   [Full Text] [Related]  

  • 39. Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control.
    Habr-Gama A; Gama-Rodrigues J; São Julião GP; Proscurshim I; Sabbagh C; Lynn PB; Perez RO
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):822-8. PubMed ID: 24495589
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Key clinical trials in rectal cancer shaping the current treatment paradigms: reference guide for radiologists.
    Paroder V; Fraum TJ; Nougaret S; Petkovska I; Rauch GM; Kaur H
    Abdom Radiol (NY); 2023 Sep; 48(9):2825-2835. PubMed ID: 37221342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.